Assembly Biosciences, Inc.

NASDAQ:ASMB

Biotechnology

Healthcare
$22.39 +0.66%

+$0.16 today

Market cap
$458.48M
Beta
1.08
P/E (TTM)
-64.4
EPS (TTM)
-$0.38
52W Low $16.50High $39.71

Volume 0.49M

Average 0.17M

ASMB Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Assembly Biosciences, Inc.NASDAQ: ASMB

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt remains negative

Q1 FY2026 net debt was -$28.63M, compared with -$20.39M a year earlier.

Context

  • Net debt amounted to 12.2% of total assets at the end of Q1 FY2026, down 8.4 pp from a year earlier.
  • Net debt grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -40.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$28.63M+48.7% QoQ
Last fiscal yearDec 2025
-$55.82M-58.3% YoY
Year agoMar 2025
-$20.39M-40.4% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-40.4%——
1 year-58.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(55.82M) USD
Year-over-year change
-58.3%

Net Debt vs competitors

How ASMB compares with its peers on the latest reported figures

  • ASMB's Mar 2026 net debt of -$28.63M is the 4th highest of the 6 companies compared; the peer median is -$23.08M.
  • Its year-over-year change of -40.4% is the lowest of 6, against a peer median of +26.7%.
  • Net debt amounts to 12.2% of total assets for ASMB, versus a peer median of 29.5%.
ASMB Competitors Peer median
Net Debt for ASMB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$151.69M -2.7%—48.2%
INDPIndaptus Therapeutics, Inc.Mar 2026-$1.5M +60.9%—68.7%
ABUSArbutus Biopharma CorporationMar 2026-$23.08M +26.7%—8.3%
ASMBAssembly Biosciences, Inc.Mar 2026-$28.63M -40.4%—12.2%
AVIRAtea Pharmaceuticals, Inc.Mar 2026-$78.68M +33.3%—29.5%
VIRVir Biotechnology, Inc.Mar 2026-$180.51M -1.7%—17.6%
Peer median (excluding ASMB) -$23.08M+26.7%—29.5%

Competitors are the stored peer set for ASMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents45.63M52.42M19.84M38.34M58.45M
Short-term Investments101M39.19M110.41M73.74M189.66M
Net Receivables336K944K43K400K974K
Inventory00(3.2M)00
Other Current Assets0300K3.5M3.02M5.47M
Total Current Assets154.2M96.97M133.79M115.5M254.55M
Property, Plant & Equipment (Net)7.18M3.94M2.72M3.35M2.73M
Goodwill00000
Intangible Assets00000
Long-term Investments27.97M0000
Tax Assets00000
Other Non-current Assets1.7M889K312K312K312K
Total Non-current Assets36.86M4.83M3.04M3.67M3.04M
Total Assets191.06M101.79M136.82M119.17M257.59M
Account Payables2.66M2.49M461K585K1.17M
Short-term Debt00000
Tax Payables00000
Deferred Revenue0030.92M37.62M36.9M
Other Current Liabilities6.43M599K1.15M6.48M7.52M
Total Current Liabilities16.07M16.3M39.23M47.8M48.78M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)2.73M055.38M00
Other Non-current Liabilities02.73M035.38M0
Total Non-current Liabilities6.06M2.83M56.5M38.01M2.06M
Total Liabilities22.13M19.13M95.73M85.81M50.84M
Common Stock48K4K5K7K16K
Retained Earnings(631.43M)(724.52M)(785.75M)(825.93M)(832.05M)
Accumulated OCI(419K)(803K)(81K)(211K)(41K)
Other Stockholders Equity0(1)000
Minority Interest00000
Total Equity168.93M82.66M41.1M33.36M206.75M
Total Debt6.48M3.47M2.34M3.09M2.63M
Net Debt(39.15M)(48.95M)(17.5M)(35.26M)(55.82M)

Assembly Biosciences, Inc.

NASDAQ:ASMB

Intrinsic Alpha fair value

Locked

Current Price

$22.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.